drugset / Trial / NCT02462031
To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects
RandomizedParallel-groupDouble-blind
Summary
To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral dosing in the fed state in obese or overweight subjects.
Timeline
- Start
- 2015-03
- Primary completion
- 2016-01
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KD101 | Unknown | 200 mg | Oral |
| Subject | KD101 | Unknown | 400 mg | Oral |
| Subject | KD101 | Unknown | 800 mg | Oral |
| Subject | KD101 | Unknown | 1400 mg | Oral |